In the multistep process of tumor development , several events occur to transform cells from normal to malignant. Although p53 is one of the most commonly mutated genes in a wide variety of tumors, how other genes interact with p53 to transform cells is only just beginning to be understood . To study the effects of the interaction of the Fas system with p53 in tumor progression and development , mice with a targeted disruption of the p53 tumor supressor gene and a mutation in Fas ligand were bred. Organ weights, life expectanc y, and tumor and tissue histology were assessed. Although spleen weights were drastically increased in FasL / p53 / mice, the FasL de ciency had no effect on life expectancy or the tumor spectrum of homozygous p53-de cient mice. The FasL de ciency reduced the median time to death from 12.1 months in FasL / p53 / mice to 9.6 months in FasL / p53 / mice, and led to a shift in tumor spectrum from predominantly sarcomas (63%) when FasL was present to a large number of lymphomas (76%) in FasL / p53 / mice. Given the reduced life span and increased incidence of lymphoma in FasL / p53 / mice, these mice could be useful in carcinogenicity testing, particularly for understandin g mechanisms of compound s that are nongenotoxic .
INTRODUCTION
Mice carrying gene mutations that inactivate tumor supressor genes or that lead to overexpression of activated forms of oncogenes have been used successfully to link genes with different steps in tumor progression. One advantage to using the mouse model to study cancer, is the ability to cross mice with different gene mutations to assess the potential interactions of these genes in tumor formation. This strategy has been employed in assessing the interaction of oncogenic ras (34) , tumor supressor Nf-2 (23) , and Rb (17, 35) with p53. The role of Fas in hematopoietic tumorigenesis has also been demonstrated in crosses of Fas mutant mice (lpr) with El -myc transgenic mice (42) , T cell de cient mice (29) , or transgenic bcl-2 mice (38) ; in all cases the mice with double gene mutations developed B-cell lymphomas or myeloid leukemia at a higher incidence than the mice with the single gene alterations. We employed this strategy to assess the interaction of FasL and p53 in tumorigenesis.
Fas and FasL, although not oncogenes or tumor supressors, are thought to be used by the immune system to rid the body of abnormal cells through programmed cell death. In fact, Fas was identi ed on the basis of a speci c monoclonal antibody binding that elicited cell death in B cell tumors and other leukemic cells (37) . By upregulating a soluble form of Fas or downregulating membrane-bound Fas, a tumor may be able to escape attack from immune cells [see (28) for a comprehensive review of the role of Fas in malignancy].
Alternatively, upregulation of FasL by tumor cells may help defend the tumor against activated immune cells in a tactic similarly used by immune-privileged tissues.
Fas (CD95/Apo-1/Tnfrsf6) is a cell surface protein in the tumor necrosis factor (TNF) receptor family and effects rapid apoptosis when bound by Fas ligand (FasL/CD95L/Tnfsf6) [for a review, see (26) ]. Like TNF receptor, the extracellular domain of Fas contains several cysteine rich domains that mediate its interaction with the ligand, and the intracellular portion of Fas contains a death domain that mediates the interaction of the cytoplasmic portion of the receptor with caspases-the executioners of cell death.
An important advance to the study of Fas-mediated apoptosis was the identi cation of several spontaneous mutations in mouse genes that lead to a common set of disorders of the immune system (41, 22) . Mice expressing a mutant Fas receptor (lpr and lpr cg ) or mutant Fas ligand (gld) accumulate nonmalignant CD3 low , Thy1 low , B220 , CD4 , CD8 T cells in spleen and lymph nodes and suffer from autoimmune disease (1, 6, 36) . FasL mutant (gld) and Fas mutant (lpr) mice have a reduced life span (approximately 5 months in the MRL strain of mouse), due to immune system pathology (5, 31) . However, the onset of the disease phenotype is largely dependent on the strain of mouse, suggesting that modifying genes play a role in the disease expression.
Aspects of the murine disease resemble those of human diseases such as systemic lupus erythematosis and autoimmune lymphoproliferative syndrome, and the Fas system has been implicated in diseases such as viral hepatitis (12), Hashimoto's thyroiditis (13) , human immunode ciency virus [see (20) for review], and autoimmune diabetes (5, 18) . Additionally, there is evidence that Fas and Fas ligand play a role 705 0192-6233/02$3.00 $0.00 in the immune-privilege status of the eye, testis, and some cancer cells (2, 14, 15, 27) .
On the other hand, the role of p53 as a tumor supressor has been extensively characterized. p53 not only is a cell cycle regulator, but also can induce apoptosis in cells and participate in DNA repair. As such, p53 interacts with other proteins as well as DNA, both as a transcription factor and a transcriptional inhibitor. Regulation of p53 occurs at several levels, including transcription expression, translation, and modifying phosphorylation and interactions with other proteins. It is one of the most studied proteins, perhaps in part because of its complexity, but also because it plays such a pivotal role in so many cellular processes.
Clinical evidence for p53 acting as a tumor supressor gene comes from data that indicates that one of the most commonly mutated genes in human cancer is p53. Additionally, Li-Fraumeni patients carry a germline mutation in p53 that makes them more susceptible to tumor formation at an early age. However, it was not until the production of p53-null mice in the early 1990s that an understanding of the role of p53 in tumor initiation and progression was gained.
Three different groups independently generated p53 knockout mice in the early 1990s. Two of these strains were on a mixed C57Bl/6 and 129/SV genetic background (8, 19) and the other was on a 129/Ola genetic background (30) . Despite potentially different modifying genes in the different strains, all 3 mouse strains had a reduced life span (living approximately 3-5 months) due to the early onset of tumors (8, 19) . They developed lymphomas predominantly, and sarcomas to a lesser extent. The 129/Ola p53 knockouts have a shorter latency period to tumor formation, and develop a small number of pituitary adenocarcinomas (30) , unlike the C57Bl/6:129/SV mice, but are otherwise remarkably similar to the 2 other strains (8, 19) . Interestingly, p53 / mice develop a different tumor spectrum than homozygous knockout mice, with a shift to a predominance of sarcomas over lymphomas (8, 16, 19, 30) .
Using a colony of mice developed in-house, the effects of a homozygous FasL mutation on the tumor progression of p53 / and p53 / mice was evaluated. Given the results of studies in which crosses with lpr mice enhanced hematopoeitic tumorigenesis (29, 38, 42) , and the propensity of p53 knockout mice to develop lymphomas (8, 19, 30) , it was hypothesized that the absence of FasL and p53 would increase the incidence of lymphoma and decrease tumor latency in mice.
MATERIALS AND METHODS

Animals
Mice on a mixed background were bred and maintained in four separate in-house colonies. Each colony was derived from crosses of F1 generation mice resulting from the cross of an initial stock of 5 p53 / male mice (C57BL/6J-Trp53 tm1Tyj ) and 15 congenic gld female mice (B6Smn C3H-Tnfsf6 gld ); (Jackson Laboratory, Bar Harbor, ME). Animals were housed in humidity (30-70%) and temperature (74 2 F) controlled rooms and maintained on an alternating 12-hour light-dark cycle. Animals had access to Purina Rodent Chow 5001 (Farmer's Exchange, Framingham, MA) and water ad libitum. All procedures involving animals were performed in accordance with the guidelines of Brown University's Institutional Animal Care and Use Committee in compliance with guidelines set by the National Institute of Health. Tail tips (0.4 cm) for genotyping were collected from 21-28-day-old mice while mice were anesthetized by inhalation of metophane (Schering-Plough, Union, NJ). Animals were individually identi ed while anesthetized, at the time the tail tips were collected. Either a unique combination of clipped toes and ear punches were used, or a transponder was implanted subcutaneousl y (BioMedic Data Systems, CO).
Animals were observed at least twice weekly for signs of tumors or death. Birth dates and approximate dates of death were recorded. Any mice that displayed dif culty breathing, wasting, large masses ( 2 cm in diameter) or that otherwise appeared to be moribund were sacri ced by CO 2 asphyxiation and necropsied, and for most animals, tissue was saved for histological analysis. Otherwise, if animals were found dead, a necropsy was performed when possible, but no tissue was saved. Animals that were alive at the end of study were included in the survival analyses as censored observations. Data for male and female mice was combined, as there was no difference in mortality data between the sexes.
Genotyping
Template DNA (25 ng) was used for a 50 ul multiplex PCR reaction containing 200 uM dNTPs (Gibco, Gaithersburg, MD), 1 PCR buffer (Perkin Elmer, Branchburg, NJ), 6 mM MgCl 2 (Perkin Elmer), 0.05 U/ul of AmpliTaq Gold (Perkin Elmer), 0.4 uM of each primer set: FasL (5 ATAGGTCTTAAGAAGACTCTCATTCAAG 3 and 5 TGATCAATTTTGAGGAATCTAAGGCC 3 ), neomycin (5 AGGTGAGATGACAGGAGATC 3 and 5 CTTGGGTG-GAGAGGCTATTC 3 ), p53 (5 GCGTCTTAGAGACAG-TTGACT 3 and 5 GGATAGGTCGGCGGTTCATGC 3 ). The reaction was incubated in a Perkin Elmer 2400 Thermocycler: 95 C for 10 minutes, followed by 30 cycles of 95 C for 30 seconds, 55 C for 30 seconds, and 72 C for 30 seconds, ending with 72 C for 5 minutes. To identify the presence or absence of the FasL mutation in gld mice, a restriction digest was performed using 15 ul of the PCR product, 1 ul of StuI (Gibco, Gaithersburg, MD) and 0.5 ul of 1 M NaCl. The samples were incubated for 3 hours at 37 C followed by 10 minutes at 65 C. The resulting product was separated on a 2.5% agarose gel, and the presence or absence of bands at 112 bp, 136 bp, 280 bp, and 458 bp indicated the presence of a wild-type FasL allele, a gld mutant FasL allele, a p53 knockout allele, or a p53 wild-type allele, respectively. The resulting gel was photographed under UV-transillumination.
Organ Weights
Thymus and liver weights were measured on wild-type, FasL / p53 / , FasL / p53 / and FasL / p53 / male mice that were 12 weeks and 15 weeks old. Spleen and body weights were taken on mice at 3 weeks (N 2-5), 5 weeks (N 14-32), 12 weeks (N 6-8), and 15 weeks (N 2-5) of age. Additionally, thymus, liver, and spleen weights were measured on animals that were moribund or otherwise euthanized because of dif culty breathing, wasting, or large masses.
Histology
Tissues were xed in 10% neutral buffered formalin and embedded in paraf n. Tissues were sectioned (5 l m) and stained with hematoxylin and eosin. In general, tissues examined included kidney, liver, spleen, thymus, lymph nodes, and any grossly apparent tumors.
Statistics
Organ weights were analyzed by ANOVA followed by a Fisher's protected least signi cant differences test. The mean and standard error of the mean were calculated for each data point. Survival curves were generated using survival actuarial analysis in StatView 4.1 software. Statistical signi cance ( p < 0.05) was determined by a log-rank Mantel-Cox test.
RESULTS
Life Expectancy
The mean and median times to death were markedly lower in all 5 mutant genotypes evaluated (FasL / p53 / , FasL / p53 / , FasL / p53 / , FasL / p53 / , FasL / p53 / ) compared to wild-type controls ( Table 1 ). The life expectancy of the FasL / p53 / mice was similar to that reported in the literature for gld mice (6, 7) . Similarly, the life expectancy for FasL / p53 / was consistent with that reported for p53-null mice (8, 19) . However, life expectancy for FasL / p53 / was shorter than those reported for p53 / mice-12 months vs 18 months (8, 19) , probably due to slight differences in strain.
Within this study, the median time to death was similar between FasL / p53 / and FasL / p53 / mice (Table 1) , and the survival curves of these 2 genotypes were similar (Figure 1a ), indicating that the FasL mutation did not affect survival of p53 / mice. However, the FasL de ciency combined with p53 / genotype reduced median life expectancy from 12.1 months in FasL / p53 / mice to 9.6 months in FasL / p53 / mice (Table 1 ) and signi cantly altered the survival curve ( Figure 1b ).
The Effect of the Absence of p53 and FasL on Organ Weights
As a gross measure of pathology, the effect of the combination of p53 and FasL mutations on body and organ weights were assessed in adult animals at the time of death. Specifically, spleen, thymus, liver, and body weights were taken. These organs were chosen based on several reports that indicated that: 1) the p53-null mutation increased the incidence of thymoma and marginal zone lymphoma in spleen (40) ; 2) the FasL mutation increased the incidence of nonmalignant lymphadenopathy as well as plasmacytoid tumors (6, 7); and 3) mutations in Fas or FasL led to extramedullary hematopoiesis (32). Spleen weights tended to be higher in animals with a FasL / genotype, regardless of the status of p53 ( Table 2) . FasL / p53 / and FasL / p53 / spleen weights were signi cantly higher than those of FasL / p53 / mice. There was a general trend towards increased weights in both liver and spleen as more genes were mutated (out of 4 possible alleles), but because of the differences in ages of the animals and the small number of wild-type control animals, it was dif cult to determine the signi cance of this trend. Therefore, organ weights were compared in healthy animals at weeks 3, 5, 12, and 15.
To get a general idea of the effect of the p53 and FasL mutations, 4 genotypes were assessed: FasL / p53 / , FasL / p53 / , FasL / p53 / , and FasL / p53 / . Body, liver, and thymus weights were similar among all four genotypes (data not shown). At 5 weeks, spleen weights of FasL / p53 / mice were signi cantly different from those of FasL / p53 / and FasL / p53 / mice. By 12 and 15 weeks, spleen weights of FasL / p53 / mice were signi cantly increased compared to wild-type mice (Figure 2 ). The increase in the spleen weight of p53 / FasL / mice was more than additive between the 2 gene de ciencies alone-that is, the increase in FasL / p53 / mice (303%, 12 weeks; 409%, 15 weeks) was greater than the combined increase in FasL / p53 / (118%, 12 weeks; 134%, 15 weeks) and FasL / p53 / (168%, 12 weeks; 163%, 15 weeks) mice.
Tumor Spectrum and Causes of Death
At the time of death, a gross necropsy was performed when possible. Several observations were noted in all of the mutant mouse genotypes. For example, many mutant mice had enlarged lymph nodes, spleens, and livers. Lymph nodes were often hemorrhagic and even necrotic in a few cases. Enlarged spleens often had diffuse white foci of varying sizes. Several animals had pale liver and kidneys. Solid tumor masses were observed frequently in FasL / p53 / , FasL / p53 / , FasL / p53 / , and FasL / p53 / mice and were associated with a variety of tissues: vertebrae, bladder, kidney, mandible, skeletal muscle, liver, and thymus. None of these observations were seen in wild-type mice. Other causes of death included isolated incidences of hydrocephaly (FasL / p53 / ), renal failure (FasL / p53 / ), sepsis (FasL / p53 / ), and maloccluded incisors (FasL / p53 / and FasL / p53 / ). Several FasL / p53 / and wild-type animals were euthanized due to skin lesions and erythema and scabbing of the tail, paws, and ears. In several instances the cause of death could not be determined.
To characterize in greater detail the nature of the organ enlargements and tumors observed at necropsy in these mice, histopathologica l examinations were performed on a majority of the animals. Tissues examined typically included spleen, liver, kidney, thymus, lymph nodes, and neoplastic masses. For comparison, normal spleen is shown (Figure 3a) .
FasL / p53 / mice typically had enlarged spleens and lymph nodes. Microscopically, the enlarged spleens were characterized by a marked expansion of the white pulp with a mixture of lymphoid cells, and by extramedullary hematopoiesis (Figure 3b ). The liver in FasL / p53 / mice showed a marked accumulation of lymphoid cells in the portal areas. At higher power, a polymorphous mixture of cells were seen, including plasma cells, a variety of lymphoid cells, and hematopoietic elements including megakaryocytes. Of 4 FasL / p53 / mice examined microscopically, none had a monomorphic proliferation of lymphoid cells suggesting the presence of lymphoma; instead, all were characterized by a polymorphous accumulation of lymphoid elements and by extramedullary hematopoiesis.
FasL / p53 / mice, FasL / p53 / mice, FasL / p53 / mice, and FasL / p53 / mice frequently showed monomorphous accumulations of lymphoid cells in the spleen, liver, thymus, and lymph nodes characteristic of lymphoma. A variety of types of lymphoma were observed, including marginal zone lymphoma (Figure 3c ), diffuse large cell lymphoma (Figure 3d ), and thymic lymphoblastic lymphoma. The liver was frequently involved by these lymphomas with in ltration of portal areas. Massively enlarged lymph nodes were diffusely replaced by lymphoma in these mice.
Solid tumors examined histologically included several subcutaneous masses, tumors in the peritoneal cavity, tumors associated with bone and masses associated with skeletal muscle. They were typically rm and invaded adjacent structures. Microscopic examination con rmed that these masses were sarcomas with a variety of histological appearances. The most frequent pattern was of undifferentiated spindle-type cells, although several tumors contained areas with extremely bizarre, very large, polyploid cells. Some tumors showed differing degrees of differentiation, and could be identied as angiosarcomas, rhabdomyosarcomas, and osteosarcomas. In general, these sarcomas were solitary masses manifesting aggressive local invasion into surrounding tissues. and lymphoma (j ) in FasL-and p53-de cient mice. Several animals had evidence of both sarcoma and lymphoma or neither, making the total incidence more or less than 100% in some cases. FasL / p53 / , n 25; FasL / p53 / , n 19; FasL / p53 / , n 24; FasL / p53 / , n 21.
Occasionally, the tumors spread more widely and multiple tumor nodules were apparent (Figure 3e and 3f) .
The Effects of the FasL Mutation on the p53 / Tumor Spectrum p53 knockout mice have a high incidence of lymphoma (>70%), and sarcoma (25%) (8, 19) . Consistent with this reported data, FasL / p53 / mice had a 72% incidence of lymphoma, and a 32% incidence of sarcoma (Figure 4 ). This high incidence of lymphoma in p53 / mice was unaffected by the FasL de ciency. Wild-type and FasL / p53 / mice had no evidence of either lymphoma or sarcoma.
FasL / p53 / mice had a higher incidence of sarcoma (63%) than lymphoma (21%) (Figure 4 ). This rate is also consistent with published reports: 57% sarcoma vs 25% lymphoma (19) and 55% sarcoma vs 32% lymphoma (16) in p53 / mice. Surprisingly, however, the FasL de ciency in p53 / mice completely altered the tumor incidence, leading to a higher incidence of lymphoma (76%) than sarcoma (19%) (Figure 4) .
The Effect of a Subcutaneous Microchip on Life Span and Tumor Incidence
Two methods of identifying animals were used in the mouse colony, one involved clipping a unique combination of toes and ear marks; the other used a transponder chip inserted subcutaneously on the mouse's back. Interestingly, p53 / mice that had the transponder often developed sarcomas surrounding the identi cation chip, and both FasL / p53 / and FasL / p53 / mice had an increased rate of sarcomas when transponders were used to identify animals ( Table 3 ). The formation of sarcomas around the transponder chips in p53 / mice has been reported (4). Additionally, the life expectancy was reduced in FasL / p53 / mice that had transponder chips (Figure 5a ). FasL / p53 / mice similarly had a reduced life expectancy (Figure 5b ) and increased rate of sarcoma (Table 3) when the transponder chip was present. On the other hand, the presence of the transponder chip had no effect on the life expectancy of p53 / mice, regardless of the status of FasL, and only 1 of the animals with a p53 / genotype developed a tumor surrounding the identi cation chip.
DISCUSSION
Tumorigenesis is a multistep process that involves a series of genetic and epigenetic alterations, such as the activation of dominantly acting oncogenes and inactivation of tumor-suppressor genes. The series of mutations in key growth-regulatory genes in somatic cells and their progeny are regarded as 'multiple-hits' in a broader interpretation of Knudson's '2-hit' theory (21) . Given this multihit model of tumor progression, the data presented here suggests an interaction between p53 and FasL in the genetic alterations that occur during the progression to cancer. Mice with a targeted disruption of the p53 tumor supressor gene and a mutation in Fas ligand were bred with the goal of determining whether the combination of a FasL mutation and p53 mutation would alter tumorigenesis in mice. De ciencies of the Fas system and p53, independently, have both been noted to facilitate tumor progression. p53 / mice primarily develop lymphomas. However, given that the mean time to death in p53 / mice is 4.5 months, other epigenetic and/or genetic events must occur in addition to the loss of p53 before tumorigenesis takes place. De ciencies in the Fas system enhance the incidence of lymphomagenesis in myc mutant and T cell-de cient mice (29, 42) . Thus, life expectancy, organ weights, and tumor and tissue histology were assessed for this study.
A signi cant difference in life expectancy was evident between FasL / p53 / and FasL / p53 / animals. Additionally, a shift in tumor spectrum, from predominantly sarcomas in FasL / p53 / animals to mostly lymphomas in FasL / p53 / mice, indicated that although FasL does not have an affect on tumor spectrum or time to latency in p53 / mice, it does in uence carcinogenesis in p53 / mice. The presence of a subcutaneous identi cation chip further shortened life expectancy in both FasL / p53 / and FasL / p53 / mice and increased the incidence of sarcomas.
These observations in mice in which an apoptotic pathway was altered or proliferation was induced suggest that tipping the balance between cell death and proliferation in uences tumor progression. For example, the Fas system is involved in proliferative homeostasis of immune cells. Gld and lpr mice accumulate non-malignant CD3 low , Thy1 low , B220 , CD4 , CD8 T cells in both spleen and lymph nodes, and extramedullary hematopoiesis occurs in these mice as well (1, 6, 36) . Additionally, lpr and gld mice develop B-cell lymphomas later in life (7) . However, given the late onset of lymphoma, disruption of the Fas system alone is not markedly tumorigenic, and other genetic and epigenetic events must occur for tumor progression. The loss of 1 allele of p53 is one such event that highlights the role of Fas in lymphomagenesis.
Interestingly, there is a shift in the tumor spectrum from sarcoma to lymphoma in FasL / p53 / mice versus FasL / p53 / . This shift is likely related to both the role of the Fas system in limiting lymphoproliferation as well as how the timing of loss-of-heterozygosity (LOH) of p53 affects tumorigenicity.
The well-established observation that p53 / mice develop a different tumor spectrum than that of p53 / mice (8, 16, 19, 30) may help to explain the shift in tumor spectrum in FasL / p53 / vs FasL / p53 / mice. p53 heterozygote mice develop predominantly sarcomas, with lymphomas and adenocarcinomas observed less frequently, whereas p53 null mice are more prone to develop lymphomas. This change in tumor types is presumably due to the timing of the loss of heterozygosity of p53 and the importance of p53 in different tissues at different times during development. The 2-hit hypothesis proposed by Knudson in 1971 (21) submits that mutation or inactivation of both alleles of a tumor supressor gene, that is, a loss of heterozygosity, must occur for tumor formation. If this loss of heterozygosity does not occur until after the growth of the animal is complete, it is less likely to have deleterious effects. For example, thymic tissue undergoes rapid expansion early during development and might not be affected by the lack of one p53 gene in the p53 / mice, but would be affected in the p53 / mouse in which both alleles are absent during the time of rapid tissue proliferation. However, in a tissue such as muscle, which undergoes rapid proliferation later in development, a loss of the second p53 allele is more likely to have occurred in the p53 heterozygous mouse by that time.
Given the nonmalignant lymphoproliferative disorder that occurs in gld and lpr mice, one possible explanation for the increase in lymphoma incidence in FasL / p53 / mice relative to FasL / p53 / is that the LOH of p53 occurs preferentially in hematopoietic cells because the FasL deciency results in their unchecked proliferation. Although spleen weights in FasL / p53 / mice were more than double that of FasL / p53 / mice, life expectancy and tumor spectrum were similar. Thus, elimination of proliferative control alone did not increase lymphomagenesis.
Although not as broadly accepted, as a mechanism for p53 involvement in tumor progression, another possibility exists; in p53 heterozygous mice a reduction of p53 gene dosage alone could be enough to allow tumor development. Although, traditionally, it has been thought that tumor supressor genes require a loss of heterozygosity to be tumorigenic, p53 haploinsuf ciency has been shown to promote cancer formation in mice (39) . This may be due to the nature of p53 functioning as a tetramer (11); if p53 protein levels are halved due to loss of one allele, in theory, the effective concentration of tetramers would be reduced. One scenario in which p53 haploinsuf ciency might be enough to allow tumor development is one in which p53 induces parallel apoptotic pathways following DNA damage or cellular stress. Indeed, p53 has been shown, by us and others, to in uence the Fas system at a molecular level, either by upregulating Fas gene expression or by altering cellular compartmentalization of Fas (3, 10) . Additionally, p53 has been shown to upregulate bax transcription (24) . In p53 / cells, there could be enough p53 to form functional tetramers to induce transcription of both bax and Fas, albeit at lower levels. Although these lower levels of bax and Fas might be enough to induce marginal amounts of apoptosis in p53 / mice, the elimination of FasL would theoretically eliminate 1 pathway. Thus, the cell death/survival balance would be tipped toward an accumulation of lymphoid cells, and the chances of abnormal cells surviving and proliferating would increase.
Whether the susceptibility to tumor progression is due to p53 haploinsuf ency or LOH, the shift in tumor spectrum between FasL / p53 / and FasL / p53 / mice is due to the FasL mutation. Given the role of the Fas system in maintaining the proliferative/apoptotic balance in hematopoietic cells, it is likely that unchecked proliferation plays a role in lymphomagenesis in p53 / mice. Irritant-induced proliferation is another way in which the balance in cell death and division can be altered. Asbestosinduced mesothelioma is one example of how foreignbody-induced proliferation can lead to tumor formation (25) . The subcutaneous insertion of a transponder chip increased the incidence of sarcomas in both FasL / p53 / and FasL / p53 / mice and decreased life expectancy relative to mice without transponder chips. The observation that transponder chips induce sarcoma in p53 / mice has been reported and may be due to foreign-body-induced production of cellular growth factors (4) . Thus, just as we propose that the FasL de ciency allowed for unchecked proliferation in the hematopoeitic cells, and susceptibility to lymphomagenesis in p53 / mice, we also propose that the presence of a foreign body in connective tissue made sarcoma a more likely outcome in both FasL / p53 / and FasL / p53 / mice.
An exciting prospect from this research is the possibility of using the FasL / p53 / mice as a model of carcinogenicity testing. Currently, p53 / mice are being tested extensively for use in regulatory drug safety evaluation. Because of the decreased time to tumor development, p53 / mice are being considered for testing hypotheses about mechanism of drug or toxicant action, screening drugs before embarking on 2-year carcinogenicity testing, and testing potential anticancer therapies [see (33) for a review]. Because FasL / p53 / mice have an even shorter time to latency, they could be valuable tools in drug screening. Additionally, the need to nd a rodent model that can detect both genotoxic and nongenotoxic carcinogens could be met by the FasL / p53 / mice; p53 / mice are considered to be good models for genotoxic carcinogens (9), but the Fas system is more likely to be involved in non-genotoxic modes of tumor progression and is more likely to be in uenced by agents that induce cellular proliferation, for example. Because of this, these animals are attractive candidates for potential use in drug screening.
In sum, these observations suggest that the precarious genetic circumstances of p53 / cells are tipped toward tumor progression when cells are subjected to unchecked proliferation, whether it be because of the FasL de ciency or due to a foreign-body-induced cellular proliferation.
